

Institut für Molekulare Medizin und Zellforschung



# **Characterization of the atypical kinase RioK1 in *Caenorhabditis elegans* and its role in Ras-driven cancer**

Inaugural-Dissertation  
zur Erlangung der Doktorwürde  
der Fakultät für Biologie  
der Albert-Ludwigs-Universität Freiburg im Breisgau

vorgelegt von  
**Florian Weinberg**  
geboren in Freiburg im Breisgau

Freiburg im Breisgau  
Juli 2015

Table of Content

Abbreviations ..... vi

1.1 Zusammenfassung ..... 1

1.2 Summary ..... 2

2 Introduction ..... 3

2.1 Protein kinases ..... 3

2.2 Rio kinases ..... 3

2.2.1 Rio Kinases are essential co-factors of ribosomal biogenesis..... 5

2.2.2 Rio Kinases are involved in cell cycle progression..... 5

2.2.3 Rio Kinases are over-expressed in various cancer types..... 6

2.3 Signaling pathways ..... 7

2.3.1 Ras signaling ..... 7

2.3.1.1 Ras proteins act as molecular switches..... 10

2.3.1.2 Targeting mutated Ras proteins..... 11

2.3.2 NF-κB signaling .....14

2.4 Characteristics of cancer.....16

2.4.1 Lung cancer.....17

2.4.2 Breast cancer .....18

2.4.3 Colorectal cancer.....18

2.5 *Caenorhabditis elegans* as a model system .....19

2.5.1 Vulval development of *C. elegans* .....20

3 Aim of the study.....21

4 Results .....23

4.1 RioK1 was found in an RNAi screen for regulators of oncogenic Ras signaling in *Caenorhabditis elegans* .....23

4.2 Expression of *riok-1* in *Caenorhabditis elegans* .....23

4.3 Knockdown of *riok-1* in *Caenorhabditis elegans* leads to abnormal gonadal development and reduces broodsize .....27

4.4 Rio kinase expression in different mouse organs .....29

4.5 Over-expression of RioK1 in the colorectal cancer cell line Caco-2.....29

4.5.1 A mass spectrometric approach to identify novel interaction partners of RioK1 ....31

4.6 Over-expression of RioK1 in the untransformed mammary epithelial cell line MCF10A .....35

4.7 Establishment of Rio kinase knockdown in different cancer cell lines.....40

4.7.1 RioK1 knockdown in the NSCLC cancer cell lines A549 and NCI-H1299 .....40

4.7.1.1 Establishment of Rio kinase knockdown in A549 cells..... 40

4.7.1.2 Loss of RioK1 in NCI-H1299 cells impairs proliferation in conventional and 3D culture systems..... 42

4.7.1.3 Identification of novel RioK1 effector proteins by SILAC-based mass spectrometry....	44
4.7.1.4 RioK1 effector pathways were identified by an antibody microarray .....	45
4.7.1.5 RioK1 knockdown blocks cell cycle progression at the G2/M transition .....	47
4.7.1.6 RioK1 depletion results in reduced cell metabolic activity .....	48
4.7.1.7 Loss of RioK1 does not induce cell death but senescence .....	48
4.7.1.8 Influence of RioK1 on Ras-activated pathways .....	50
4.7.1.9 RioK1 promotes cell invasiveness by activating NF- $\kappa$ B signaling.....	50
4.7.1.10 Inhibition of the NF- $\kappa$ B pathway phenocopies the loss of RioK1 in NCI-H1299 in 3D matrix culture .....	52
4.7.1.11 RioK1 knockdown or inhibition of NF- $\kappa$ B signaling prevents the formation of invasive filopodia-like structures in 3D matrix.....	52
4.7.1.12 RioK1 enhances the metastatic potential of NCI-H1229 cells to the lung in vivo.....	55
4.7.1.13 An attempt to restore NCI-H1299 cell proliferation by over-expression of mutant RioK1 constructs.....	61
4.8 Direct protein interaction partners of RioK1 .....	64
4.9 Knockdown of RioK1 in the Ras-driven breast cancer cell line MDA-MB-231 and the colorectal cancer cell line SW480 inhibits proliferation .....	71
4.9.1 Knockdown of RioK1 in MDA-MB-231 cells impairs growth and cell metabolism ..	71
4.9.2 Knockdown of RioK1 in SW480 cells reduces cell proliferation but does not influence the expression of RioK1 effector proteins .....	73
4.9.2.1 Over-expression of RioK1 in-SW480 does not affect cell proliferation .....	76
4.10 SW620 cells are not affected by RioK1 knockdown .....	77
4.11 RioK1 knockdown has no significant impact on cancer cells lacking Ras mutations..	79
4.11.1 Knockdown of RioK1 in the colorectal cancer cell line RKO hardly impairs proliferation .....	79
4.11.2 K562 cells are non-responsive to modulation of RioK1 expression.....	81
4.12 RioK1 knockdown in the non-transformed mammary epithelial cell line MCF10A does not impair cell proliferation .....	83
4.13 Analysis of identified RioK1 effectors in the RioK1 over-expressing MCF10Atet and Caco-2tet cell lines.....	86
4.14 Immuno-histochemistry of patient derived tumor specimens .....	90
5 Discussion.....	92
5.1 Expression pattern analysis and functional characterization of <i>riok-1</i> in <i>Caenorhabditis elegans</i> .....	92
5.2 Rio kinase expression in the mouse.....	93
5.3 Inducible gene expression and gene suppression systems .....	93
5.4 Caco-2 cells react to RioK1 over-expression with morphological changes and invasive growth.....	94
5.5 Analysis of growth factor stimulated signaling cascades in MCF10A cells over-expressing RioK1 .....	95

5.6 RioK1 knockdown impairs cell viability of oncogenic Ras-driven cancer cells. ....	96
5.6.1 Establishment of knockdown cell lines .....	96
5.6.2 Knockdown of RioK1 but not of RioK2 or RioK3 impaires cell proliferation .....	96
5.6.3 Identification of RioK1 signaling pathways and effector proteins.....	97
5.6.3.1 RioK1 knockdown impairs the cell metabolism of Ras-driven cancer cells.....	98
5.6.3.2 Novel interaction partners and effectors of RioK1 .....	98
5.6.3.2.1 RioK1 knockdown blocks cell cycle progression at the G2 to M transition.....	98
5.6.3.2.2 Rio kinases form homo- and heterodimers.....	98
5.6.3.2.3 CDK1, LARP1, Stathmin1 and Metadherin, novel substrates of RioK1? .....	99
5.6.4 RioK1 is part of the NF- $\kappa$ B signaling pathway.....	100
5.7 RioK1 promotes metastasis to the lung <i>in vivo</i> .....	103
5.8 RioK1, a promising target for Ras-driven tumors? .....	103
6 Conclusion and outlook .....	106
7 Material .....	107
7.1 Cells.....	107
7.2 Worm strains.....	107
7.3 Media .....	107
7.4 Reagents and inhibitors for cell culture .....	108
7.5 Antibodies .....	109
7.5.1 Primary antibodies.....	109
7.5.2 Secondary antibodies (horse-radish peroxidase conjugated).....	110
7.5.3 Antibodies and compounds used for immuno-fluorescence .....	110
7.6 Bacteria used for cloning and worm feeding.....	110
7.7 Chemicals .....	111
7.8 Buffers and solutions .....	113
7.9 Oligo-nucleotides .....	115
7.10 Plasmids .....	117
7.10.1 cDNA plasmids.....	117
7.10.2 shRNA plasmids.....	118
7.10.3 Plasmids used for <i>C. elegans</i> .....	118
7.11 Kits.....	119
7.12 Enzymes .....	119
7.13 Laboratory equipment .....	119
7.14 Consumables .....	121
7.15 Software.....	121
7.16 Websites .....	122
8 Methods .....	123
8.1 Mammalian cell culture .....	123

8.1.1 Cultivation of cells.....	123
8.1.2 Counting of cells.....	123
8.1.3 Cryo-conservation of cells .....	123
8.1.4 Transfection of cells.....	123
8.1.5 Retroviral infection of cells.....	123
8.1.6 Lentiviral infection of cells.....	124
8.1.7 Generation of cell lines by electroporation or nucleofection .....	124
8.1.8 MTT-Assay.....	124
8.1.9 Caspase3-Assay .....	124
8.1.10 NF- $\kappa$ B Luciferase reporter assay .....	125
8.1.11 Senescence staining .....	125
8.1.12 Colony Formation Assay (CFA) .....	125
8.1.13 Three-dimensional matrix culture.....	125
8.1.14 Immuno-fluorescence (IF).....	125
8.1.15 Imaging .....	126
8.1.16 Flow cytometry .....	126
8.1.17 Stable isotop labeling in cell culture (SILAC) .....	126
8.1 18 Xenograft experiments and isolation of tissue samples.....	126
8.1.19 Preparation of tissue samples and immuno-histochemistry .....	127
8.2 Biochemical methods.....	128
8.2.1 Preparation of total cell lysates (TCL).....	128
8.2.2 Immuno-precipitation (IP) .....	128
8.2.3 SDS-PAGE.....	129
8.2.4 Western blotting .....	129
8.2.6 Statistical analysis of western blot detections .....	129
8.2.7 Mass spectrometry .....	129
8.3 Cloning .....	130
8.3.1 Polymerase Chain Reaction (PCR) .....	130
8.3.1.1 Touchdown-PCR .....	130
8.3.1.2 Site-directed mutagenesis (SDM).....	131
8.3.2 Transformation of <i>E. coli</i> .....	131
8.3.3 Cryo-conservation of <i>E. coli</i> .....	131
8.3.4 DNA preparation.....	131
8.3.5 Measurement of DNA concentration und purity .....	131
8.3.6 DNA sequencing.....	132
8.3.7 Enzymatic DNA digest, DNA analysis by electrophoresis and isolation of DNA fragments for cloning.....	132
8.3.8 DNA cloning by enzymatic digest ligation .....	132

8.3.8.1 Verification of DNA plasmids by colony PCR, enzymatic digest or blue/white screening .....	132
8.4 <i>Caenorhabditis elegans</i> methods .....	133
8.4.1 Worm maintenance .....	133
8.4.2 Generation of transgenic worm lines by microinjection .....	133
8.4.3 RNAi to repress protein expression in <i>C. elegans</i> .....	133
8.4.4 Worm imaging .....	133
9 Appendix .....	134
9.1 Supplementary figure .....	134
9.2 DNA constructs used in this study.....	135
9.3 Supplementary tables: .....	137
10 References .....	142
11 Danksagung .....	157